Diabetes and atrial fibrillation: stratification and prevention of stroke risks by Stephan v Bandemer et al.
v Bandemer et al. The EPMA Journal 2014, 5:17
http://www.epmajournal.com/content/5/1/17RESEARCH Open AccessDiabetes and atrial fibrillation: stratification and
prevention of stroke risks
Stephan v Bandemer1*, Sebastian Merkel1, Anna Nimako-Doffour1 and Mattias M Weber2Abstract
Background: Although evidence is not very clear, diabetes is assumed to be an independent risk factor for atrial
fibrillation (AF). One reason for the lack of evidence could be that AF often is not detected due to its paroxysmal or
asymptomatic character. A better understanding of the relationship between both diseases and improved detection
of AF is necessary since the combination of both diseases dramatically increase the risk of strokes if not treated
properly.
Methods: Available literature about diabetes as an independent risk factor for AF has been evaluated, and
limitations of studies are discussed.
Results: Results from different trials and registers are contradictory concerning diabetes as an independent risk
factor for AF. Reasons for these differences can be found in different study designs and neglecting patients with
unknown AF.
Conclusions: Due to the increasing burden of disease of diabetes and AF as common risk factors for stroke, a
systematic screening for AF in diabetes patients could provide a better understanding of their correlation and
personalized prevention strategies.
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Predictive, preventive and personalized medicine in the
case of diabetes and AF
Diabetes and predictive, preventive and personalized
medicine (PPPM) have been the focus of EPMA since its
inception [1]. Especially, biomarkers for the prediction
of diabetes complications [2-4], specific complications
like diabetic retinopathy [5] or cancer [6] as well as
questions of drug delivery [7,8] have been addressed by
the research. The first EPMA World Congress in 2011
addressed public health issues, diabetes education and
lifestyle changes and dealt with genomics, proteomics
and metabolomics identifying individuals at risk of de-
veloping the disease [9].
At the second EPMA World Congress in 2013, among
other topics, problems of multimorbidity of diabetic pa-
tients were further stressed [10]. This raises the question
whether diabetes has to be considered as an independent* Correspondence: bandemer@iat.eu
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article, unless otherwise stated.risk factor for other diseases (e.g. atrial fibrillation (AF))
and how the combination of diseases with different eti-
ologies increase the risk of severe complications like
heart diseases and stroke. This paper addresses the ques-
tion of the interdependency between diabetes and AF as
a major stroke risk and discusses research requirements
in order to advance the understanding of multimorbidity
in diabetes patients as a prerequisite of appropriate pre-
vention strategies.Epidemiology of diabetes and atrial fibrillation
Diabetes is one of the biggest epidemiological challenges
worldwide. According to the International Diabetes Fed-
eration, 366 million people suffered from diabetes type 1
and type 2 in 2011. By 2030, this number will increase
to 552 million people. Diabetes caused 4.6 million deaths
in 2011 and at least 465 billion dollars of health care ex-
penditures, being responsible for 11% of total health care
expenditures [11].
Diabetes-associated AF is a chronic disease with high
prevalence and a progressive increase in its severityntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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and death [12,13]. Based on the analysis of the Rotterdam
cohort study [14], the total prevalence of AF is 8.6 in men
and 7.1 in women. The prevalence increases with age from
1.3/1.7 in the population between 55 and 59 years to 24.2/
16.1 in the population above 85 years. Projected age- and
sex-adjusted prevalence for the European Union will
more than double from 8.8 Mio. in 2010 to 17.9 Mio.
in 2060 [15].
The need for better prevention and treatment of dia-
betes and AF is complicated by a lack of knowledge
about diabetes as an independent risk factor for AF and
problems in detecting AF as a risk factor for stroke espe-
cially in combination with diabetes. Therefore, the ana-
lysis of the multimorbidity of patients is an important
task in order to stratify risks and risk prevention strat-
egies for individual patients.
Methods
An evaluation of available literature, trials and registers
about diabetes as an independent risk factor for AF
shows contradictory results. Possible reasons for these
differences are discussed, and options for overcoming
limitations of existing studies are debated. Limitations of
the available literature are that there are no studies avail-
able which are based on AF screening in patients with
diabetes.
Results
Diabetes as an independent risk factor for AF and
associated stroke risk
The evaluation of literature about the relation of dia-
betes as an independent risk factor for AF can be based
on different types of studies. Some registers and epi-
demiological studies provide quantitative data about the
relation of diabetes and AF [15-19]. This literature has
its limitations especially in a lack of adjustments of com-
mon risks of diabetes and AF and does not provide de-
tails about the diseases. Other studies additionally take
common risk factors of diabetes and AF as well as dia-
betes duration and glucose control into account [20,21].
These studies however do not address detection prob-
lems of AF and seem to underestimate prevalence. Some
studies are available about the detection of unknown AF
in the case of (cryptogenic) strokes, but they do not
analyze the relation to diabetes systematically [22-24].
Large registries like RE-LY AF show that the preva-
lence of diabetes in patients with AF is high (21.8)
[15,16]. However, the age-adjusted prevalence does not
seem to be significantly higher than that in the overall
population [25]. These epidemiological data cannot pro-
vide reasonable evidence for diabetes as an independent
risk factor for AF. Many studies have analyzed just this
relation of AF to diabetes or elevated blood glucose asindependent risk factors, but results are contradictory.
The Framingham Heart Study mentions diabetes as an
independent risk factor for AF [17], but the Framingham
risk score for AF only confirms known risk factors for
AF such as age, sex, body mass index, blood pressure
and cardiovascular disease, not diabetes however (OR
1.10; CI 0.87–1.38) [18]. Other studies see an association
between diabetes and AF for women but not for men [19].
One reason for the different results could be that both
diseases have similar risk factors like age or obesity.
Also, paroxysmal AF might be neglected due to detec-
tion problems. A study that adjusted age and BMI risks
and included all kinds of AF reflecting especially on the
role of diabetes duration and glycemic control found an
elevated AF risk with diabetes duration and poor gly-
cemic control [21]. In this study, people with diabetes
treatment had an overall 40% increased risk for AF com-
pared to those without diabetes (95% CI 1.15–1.71). The
risk for AF increased by 3% for every year of diabetes
duration (95% CI 1%–6%) and was higher in patients
with poor glycemic control. The NAVIGATOR trial ana-
lyzed incident AF in patients with no AF in their medical
history. It showed that patients with impaired glucose tol-
erance but no progression to diabetes had a 33% (CI 1.11–
1.59) risk increase for AF per 1 mmol/L fasting plasma
glucose. However, this trial could not confirm the progres-
sion of diabetes as an independent risk factor for AF (HR
0.98, CI 0.80, 1.20) [21]. Thus, there exists at least some
evidence for an elevated risk of AF in patients with glu-
cose intolerance or diabetes, but there also are quite some
contradictions between different trials.
A limitation of studies about the relation of diabetes
and AF is undiagnosed AF (silent AF) since it often is
asymptomatic even in the case of permanent AF. Also,
in many cases, AF is paroxysmal and difficult to detect
[26]. In 15% to 25% of patients with stroke, AF is first
detected at the time of stroke incident [22]. And even at
stroke incident, AF is often not detected. About 30% of
strokes remain cryptogenic [27]. A recent study using
automated continuous ECG monitoring during stroke
unit stay detected AF in 13.7% of patients who did not
have known AF episodes in their medical history and
not at admission ECG. Of these patients, 24.6% also had
diabetes [23]. In the Cryptogenic Stroke and Underlying
Atrial Fibrillation (CRYSTAL-AF) trial which traced 220
patients with cryptogenic stroke by an implantable loop
recorder, 29 cases of AF have been detected. The mean
time for detection was 84 days [24]. This indicates that
AF and the related stroke risks are easily underestimated
which might distort results of trials.
Expert recommendations
Considering that diabetes as well as AF goes along with
an approximately up to fourfold stroke risk each [28,29]
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diabetic patients, prevention strategies addressing the
multimorbidity of the diseases are of substantial rele-
vance. There are gaps in the knowledge about subgroups
of patients according to age, sex, ethnicity and socioeco-
nomic status. A subgroup analysis of patients will be neces-
sary in order to personalize prevention strategies. Research
also has to focus on the interrelationship between diabetes
and AF and common risk factors such as age and obesity
which can predispose to these conditions.
Primary prevention
Since the risk of stroke increases considerably for dia-
betic patients even with undetected AF or AF without
symptoms [30], it will be of high relevance to screen dia-
betic patients for all kinds of AF systematically. Some
cases may be detected by conventional 12-lead ECG, but
this will miss those patients with paroxysmal AF and no
episode during ECG. The use of Holter ECG will also
miss many patients in the case of paroxysmal AF. The
CRYSTAL-AF study therefore suggests the use of loop
recorders for such screening even in primary prevention
[24]. However, due to high costs and the interventional
character, economic reasons as well as patient’s accept-
ance will limit this approach. A promising alternative
would be the automated ECG that has provided high
specificity and significance in patients with cryptogenic
stroke [23].
In order to stratify individual risks of patients with dia-
betes without a medical history of AF, a screening for
AF would at least be appropriate in the case of one add-
itional risk factor according to the CHADS2 score since
these patients will definitely profit from oral anticoagula-
tion (OAC) considerably [31,32]. But even diabetic pa-
tients without additional risk factors should be eligible
for participating in an AF screening since individual de-
cisions for antiplatelet or OAC will have to be taken.
This will also provide the opportunity for a stratification
of diabetic patients who will rather benefit from treat-
ment with new oral anticoagulants (NOACs) and those
who will rather need treatment with vitamin K antago-
nists. Many diabetes patients will have contraindication
for NOACs due to co-morbidities like impaired kidney
function and therefore need treatment with warfarin.
Co-morbidities like chronic wounds will also require a
therapeutic management that coordinates various risk
factors and their treatment.
In addition to the preventive purpose of screening dia-
betic patients for AF, this will provide an increasing un-
derstanding of the interrelationship between diabetes
and AF. All studies on diabetes as an independent risk
factor for AF have focused on patients with known AF
and therefore are systematically underestimating asymp-
tomatic and paroxysmal AF.Secondary and tertiary prevention
Although there have been some studies concerning sec-
ondary prevention especially concerning cryptogenic stroke
[23,24], strategies of detection still require further research.
The trials have been performed with small numbers of pa-
tients, and the stratification of diagnostic instruments
needs further validation. This concerns the combination of
automated ECGs and implantable loop recorders. Trials
also usually have concentrated on one possible reason for
cryptogenic stroke but did not address problems of multi-
morbidity like diabetes, hypertension and AF as possible
combined causes.
In order to provide appropriate secondary prevention
strategies, cryptogenic strokes need to be analyzed with
respect to multiple causes. Personalized strategies to
prevent recurrent strokes will have to address different
independent risk factors and their interactions. This re-
quires further research into interdependencies like be-
tween diabetes and AF. Secondary and tertiary prevention
of all stroke patients require consequent follow-up in
order to prevent recurrent stroke. This includes lifestyle
changes and consequent control especially of glucose
levels, anticoagulation, blood pressure and cholesterol
levels [33].
Research networks under the umbrella of EPMA
In order to cope with the increasing multimorbidity of
diabetes patients, it will be necessary to organize multi-
disciplinary teams including different medical specialties
as well as industrial partners. Research needs to be orga-
nized in a translational way including basic research
about the mechanisms of interrelationship between dia-
betes and AF, screening of AF, prevention of risk factors
and the management of complications. EPMA can pro-
vide the platform of research for individualized strategies
by cooperating with research teams from basic research
to the design of health service strategies and patient
organization involvement.
For this purpose, the cooperation with providers in
health clusters will be a promising strategy for the design
of health research and treatment strategies. Such clusters
can provide research and services along the supply chain
(Figure 1) of diabetes care and integrate the different ap-
proaches. Utilizing clusters as a basis for international
research networks will enable networks for systematic-
ally dealing with multimorbidity and translational strat-
egies as a major challenge for PPPM.
“Horizon 2020” as a powerful instrument to promote the
innovation in the field
As it has been reported in its White Paper 2012 as the
fundamental strategic document [9], EPMA has strongly
contributed to the PPPM-related topics considered within
the new European programme “Horizon 2020”. The tasks
Figure 1 Supply chain of diabetes care.
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treatments of persons affected by diabetes and its compli-
cations and co-morbidities are crucial for the scientific
progress in a spectrum of medical fields and health care as
the whole. “Horizon 2020” creates a robust platform for
the multi- and interdisciplinary professional collaboration
as the clue to the dramatic improvements in the pre/dia-
betes care. Consequently, the professional consolidation in
the field should be performed utilizing all the comprehen-
sive instruments systematically provided over the entire
duration of the European programme (2014–2020). The
complete overview of the strategies and instruments of
the “Horizon 2020” is provided by the “Predictive, Pre-
ventive and Personalised Medicine as the hardcore of
‘Horizon 2020’: EPMA position paper” [34]. In particular,
the below listed calls 2014–2015 might be useful to pro-
mote diabetes-related international collaboration, innova-
tive research and advanced health carea:
1. Understanding health, ageing and disease
PHC 1—2014: Understanding health, ageing and
disease: determinants, risk factors and pathways
PHC 2—2015: Understanding diseases: systems
medicine
PHC 3—2015: Understanding common mechanisms
of diseases and their relevance in co-morbidities
2. Effective health promotion, disease prevention,
preparedness and screening
PHC 4—2015: Health promotion and disease
prevention: improved inter-sector cooperation for
environment and health-based interventions
PHC 5—2014: Health promotion and disease
prevention: translating “omics” into stratified
approaches
PHC 6—2014: Evaluating existing screening and
prevention programmes
PHC 7—2014: Improving the control of infectious
epidemics and foodborne outbreaks through rapid
identification of pathogens (see also societal
challenge 2)
PHC 8—2014: Vaccine development for
poverty-related and neglected infectious diseases:
tuberculosisPHC 9—2015: Vaccine development for
poverty-related and neglected infectious diseases:
HIV/AIDS
3. Improving diagnosis
PHC 10—2014: Development of new diagnostic
tools and technologies: in vitro devices, assays and
platforms
PHC 11—2015: Development of new diagnostic
tools and technologies: in vivo medical imaging
technologies
PHC 12—2014/2015: Clinical research for the
validation of biomarkers and/or diagnostic medical
devices
4. Innovative treatments and technologies
PHC 13—2014: New therapies for chronic
non-communicable diseases
PHC 14—2015: New therapies for rare diseases
PHC 15—2014/2015: Clinical research on
regenerative medicine
PHC 16—2015: Tools and technologies for
advanced therapies
PHC 17—2014: Comparing the effectiveness of
existing health care interventions in the elderly
PHC 18—2015: Establishing effectiveness of health
care interventions in the paediatric population
5. Advancing active and healthy ageing
PHC 19—2014: Advancing active and healthy
ageing with ICT: service robotics within assisted
living environments
PHC 20—2014: Advancing active and healthy
ageing with ICT: ICT solutions for independent
living with cognitive impairment
PHC 21—2015: Advancing active and healthy
ageing with ICT: early risk detection and
intervention
6. Integrated, sustainable, citizen-centred care
PHC 23—2014: Developing and comparing new
models for safe and efficient, prevention-oriented
health and care systems
PHC 24—2015: Piloting personalized medicine in
health and care systems
PHC 25—2015: Advanced ICT systems and services
for integrated care
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disease: citizen engagement and mHealth
PHC 27—2015: Self-management of health and
disease and patient empowerment supported by
ICT
PHC 28—2015: Self-management of health and
disease and decision support systems based on
predictive computer modelling used by the patient
him or herself
PHC 29—2015: Public procurement of innovative
eHealth services
7. Improving health information, data exploitation and
providing an evidence base for health policies and
regulation
PHC 30—2015: Digital representation of health
data to improve disease diagnosis and treatment
PHC 31—2014: Foresight for health policy
development and regulation
PHC 32—2014: Advancing bioinformatics to meet
biomedical and clinical needs
PHC 33—2015: New approaches to improve
predictive human safety testing
PHC 34—2014: eHealth interoperability
Co-ordination activities:
HCO 1—2014: Support for the European Innovation
Partnership on Active and Healthy Ageing
HCO 2—2014: Joint Programming: Coordination Action
for the Joint Programming Initiative (JPI) “More Years,
Better Lives - the Challenges and Opportunities of
Demographic Change”
HCO 3—2015: Support for the European Reference
Networks: efficient network modelling and validation
HCO 4—2014: Support for international infectious
disease preparedness research
HCO 5—2014: Global Alliance for Chronic Diseases:
prevention and treatment of type 2 diabetes
HCO 6—2015: Global Alliance for Chronic Diseases:
2015 priority
HCO 7—2014: ERA-NET: establishing synergies between
the Joint Programming on Neurodegenerative Diseases
Research and Horizon 2020
HCO 8—2014: ERA-NET: aligning national/regional
translational cancer research programmes and activities
HCO 9—2014: ERA-NET: systems medicine to address
clinical needs
HCO 10—2014: ERA NET: rare disease research
implementing IRDiRC objectives
HCO 11—2015: ERA-NET: collaboration and alignment
of national programmes and activities in the area of
brain-related diseases and disorders of the nervous
system
HCO 12—2015: ERA-NET: antimicrobial resistanceHCO 13—2015: ERA-NET: cardiovascular disease
HCO 14—2014: Bridging the divide in European health
research and innovation
HCO 15—2014: Mobilization and mutual learning
action plan
HCO 16—2014: National Contact Points
Further, it is highly recommended to analyze systematic-
ally the proposals which have been approved and disap-
proved within “Horizon 2020” with follow-up evaluation
of the impacts of corresponding projects which have
received financial supported from the EU. EPMA con-
sortium is requested to coordinate these activities at
the EU level.
Endnote
aCalls with potential relevance for diabetes care are in
italics.
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